Long-term 340B participation is linked to stronger financial assets, with much of the program’s recent growth flowing

Examining the drivers of 340B drug program growth, the impact of vertical integration and contract pharmacies, the ongoing legal and regulatory disputes, and the strategic considerations life sciences companies must navigate in this evolving landscape.

A clear look at the 340B program: how hospitals generate revenue from drug discounts, why it has expanded, and the growing policy debate.

The Health Resources and Services Administration ("HRSA") plans to implement a limited pilot program that will allow approved manufacturers to issue post-purchase rebates for 340B covered outpatient drugs rather than upfront discounts. On August 1, 2025 ...

Careful analysis of the seemingly intractable problem of rising medical costs can typically be reduced to three things: 1) who pays? (the accustomed answer generally being “someone else”); 2) the creeping role of the federal government in making that determination;

Illinois lawmakers passed two bills balancing hospital protections and audits for the federal 340B drug program.

The federal 340B Drug Pricing Program ("340B Program") was created by Congress in 1992 through an amendment to the Public Health Service Act. [i] The program, which is administered by the Health Resources & Services Administration ("HRSA"), was intended to ...

Although 340B does not operate through the tax code, its economic effects mirror those of a tax expenditure. Recognizing it as such would not prejudge the program’s merits but would force a long-overdue accounting of its costs and encourage a more ...